Gregory F. Guzauskas

Health Economics and Outcomes Research (United Kingdom)

Economics, Econometrics and FinanceBiochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China”.

The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China

Pain and Therapy(2016)10.1007/s40122-016-0048-z

N/A

0.425DataRank · unranked

16 citations

Dongdong Liu, Wesley E. Furnback, Fan Bifa, Peng Dong, Li Xie +3 more

The estimated costs and benefits of a hypothetical supervised consumption site in Providence, Rhode Island

International Journal of Drug Policy(2022)10.1016/j.drugpo.2022.103820

N/A

0.385DataRank · unranked

12 citations

Benjamin D. Hallowell, Xiao Zang, David M. Rind, Gregory F. Guzauskas, Ryan N. Hansen +4 more